Cypherpunk Technologies Inc. (CYPH)

NCM – Real Time Price. Currency in USD

0.68

-0.00 (-0.13%)

Market open: Aug 12, 2026, 2:25 PM EDT

0.69

+0.01 (2.00%)

Previous after-hours: Aug 11, 2026, 7:59 PM EDT

12.08.2026

Cypherpunk Technologies Reports Second Quarter 2026 Financial Results

CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypherpunk"), today reported financial results for the second quarter ended June 30, 2026.

12.08.2026

Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research

Peer-reviewed analyses establish baseline plasma DKK1 as a continuous quantitative biomarker predicting deepening sirexatamab benefit in 2L mCRC patients In DKK1-high 2L mCRC patients, sirexatamab improved response, progression-free survival, and overall survival when added to bevacizumab and chemotherapy CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Leap Therapeutics, Inc., the biotechnology subsidiary of Cypherpunk Technologies Inc. (Nasdaq: CYPH), today announced the publication of results from the randomized Phase 2 DeFianCe study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in Clinical Cancer Research.

Videos

No Data

There is no data to display

Press releases

12.08.2026

Cypherpunk Technologies Reports Second Quarter 2026 Financial Results

CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypherpunk"), today reported financial results for the second quarter ended June 30, 2026.

12.08.2026

Cypherpunk Technologies Inc. (CYPH)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Cypherpunk Technologies Inc. (CYPH)

Cypherpunk Technologies Reports Second Quarter 2026 Financial Results

Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research

Videos

No Data

Press releases

Cypherpunk Technologies Reports Second Quarter 2026 Financial Results

Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research

Cypherpunk Technologies Reports Second Quarter 2026 Financial Results

Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research

Videos

No Data

Press releases

Cypherpunk Technologies Reports Second Quarter 2026 Financial Results

Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research

Search stocks

Cypherpunk Technologies Inc. (CYPH)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Cypherpunk Technologies Inc. (CYPH)

Cypherpunk Technologies Reports Second Quarter 2026 Financial Results

Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research

Videos

No Data

Press releases

Cypherpunk Technologies Reports Second Quarter 2026 Financial Results

Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research

Cypherpunk Technologies Reports Second Quarter 2026 Financial Results

Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research

Videos

No Data

Press releases

Cypherpunk Technologies Reports Second Quarter 2026 Financial Results

Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research